US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

CLIMB BIO INC

13.67

-0.9000-6.18%

Volume:868.57K

Turnover:12.16M

Market Cap:782.75M

PE:-16.38

High:14.70

Open:14.58

Low:13.63

Close:14.57

52wk High:18.33

52wk Low:1.54

Shares:57.26M

Float Shares:41.60M

Volume Ratio:0.90

T/O Rate:2.09%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.8347

EPS(LYR):-0.8974

ROE:-27.10%

ROA:-18.45%

PB:3.27

PE(LYR):-15.23

Loading ...

Overview Company News Filings

Climb Bio's Upcoming CLYM116 Data Could Support Longer Dosing, Strong Potency, Oppenheimer Says

MT Newswires Live

Climb Bio is Maintained at Buy by HC Wainwright & Co.

Climb Bio Price Target Maintained with a $20.00/Share by Wedbush

U.S. Research Roundup- Berkshire Hathaway, Exxon Mobil, Honeywell Technologies

Climb Bio Partner Mabworks Doses First Patient in China Phase 2 IgA Nephropathy Trial

Truist Financial Sticks to Their Buy Rating for Climb Bio (CLYM)

Guggenheim Reaffirms Their Buy Rating on Climb Bio (CLYM)

RBC Capital Keeps Their Buy Rating on Climb Bio (CLYM)

Climb Bio Price Target Raised to $25.00/Share from $17.00 by Truist Securities

Analysts Are Bullish on These Healthcare Stocks: Climb Bio (CLYM), Kodiak Sciences (KOD)

Climb Bio Initiates Phase 2 Clym116 Trial in IgA Nephropathy in Q3 2026

Climb Bio Q2 EPS $(0.18) Beats $(0.21) Estimate

Benzinga Earnings

Climb Bio Q2 Net Loss Widens on Pipeline Advancement

Climb Bio Q2 FY26 Net Loss Widens 55.73% to $13.5 Million

Climb Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates

THOMSON REUTERS

Climb Bio - Financing Extends Cash Runway into Second Half of 2028

THOMSON REUTERS

Climb Bio Inc Q2 Income from Operations USD -15.359 Million

THOMSON REUTERS

Climb Bio Offers Compelling, Data-Rich H2 With Multiple Near-term Catalysts Across Two Programs, RBC Says

MT Newswires Live

Climb Bio Inc : RBC Initiates Coverage with Outperform Rating; Target Price $23

THOMSON REUTERS

Climb Bio’s Budoprutug Trial Completion Sets Stage for Next Investor Catalyst

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigermoments.com/stock/CLYM/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CLYM","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CLYM\",,,,,undefined,":{"symbol":"CLYM","market":"US","secType":"STK","nameCN":"CLIMB BIO INC","latestPrice":13.67,"timestamp":1788201280509,"preClose":14.57,"halted":0,"volume":868570,"delay":0,"changeRate":-0.06177076183939604,"floatShares":41603800,"shares":57260500,"eps":-0.83475,"marketStatus":"Trading","change":-0.9,"latestTime":"08-31 14:34:48 EDT","open":14.58,"high":14.695,"low":13.6319,"amount":12160307.45089,"amplitude":0.072965,"askPrice":13.68,"askSize":359,"bidPrice":13.66,"bidSize":264,"shortable":3,"etf":0,"ttmEps":-0.83475,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1788206400000},"marketStatusCode":2,"adr":0,"listingDate":1628222400000,"exchange":"NASDAQ","adjPreClose":14.57,"preHourTrading":{"tag":"盘前","latestPrice":14.35,"preClose":14.57,"latestTime":"09:29 EDT","volume":2351,"amount":34410.81117,"timestamp":1788182998998,"change":-0.22,"changeRate":-0.0151,"amplitude":0.113246},"postHourTrading":{"tag":"盘后","latestPrice":14.4019,"preClose":14.57,"latestTime":"19:30 EDT","volume":20820,"amount":303596.1838,"timestamp":1787959806603,"change":-0.1681,"changeRate":-0.011537,"amplitude":0.031441},"volumeRatio":0.899555,"impliedVol":1.7537,"impliedVolPercentile":0.7124},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CLYM\",,,,,undefined,":{"symbol":"CLYM","floatShares":41603800,"roa":"-18.45%","roe":"-27.10%","lyrEps":-0.897422,"volumeRatio":0.899555,"shares":57260500,"dividePrice":0,"high":14.695,"amplitude":0.072965,"preClose":14.57,"low":13.6319,"week52Low":1.54,"pbRate":"3.27","week52High":18.33,"institutionHeld":0,"latestPrice":13.67,"committee":-0.152488,"eps":-0.83475,"divideRate":0,"volume":868570,"delay":0,"ttmEps":-0.83475,"open":14.58,"prevYearClose":4,"prevWeekClose":14.57,"prevMonthClose":11.9,"prevQuarterClose":13.04,"fiveDayClose":16.4,"twentyDayClose":11.81,"sixtyDayClose":10.91},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CLYM\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-06","symbol":"CLYM","fiscalQuarterEnding":"2026/06","expectedEps":-0.22,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1785988800000,"reportTimeType":"pre","actualEps":-0.18},{"market":"US","date":"2026-05-07","symbol":"CLYM","fiscalQuarterEnding":"2026/03","expectedEps":-0.26,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778126400000,"reportTimeType":"pre","actualEps":-0.2},{"market":"US","date":"2026-03-05","symbol":"CLYM","fiscalQuarterEnding":"2025/12","expectedEps":-0.2,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1772686800000,"reportTimeType":"pre","actualEps":-0.26},{"market":"US","date":"2025-11-06","symbol":"CLYM","fiscalQuarterEnding":"2025/09","expectedEps":-0.16,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1762405200000,"reportTimeType":"pre","actualEps":-0.19},{"market":"US","date":"2025-08-12","symbol":"CLYM","fiscalQuarterEnding":"2025/06","expectedEps":-0.19,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1754971200000,"reportTimeType":"pre","actualEps":-0.13}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CLYM\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CLYM\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5333,"buy":0.4667,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5333,"analysts":15,"updateTime":1785816000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CLYM\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CLYM","date":"2026-08-28","current":-16.687631,"percent":0.023256,"low":-17.781875,"twenty":-6.894117,"median":-3.079659,"eighty":-1.243636,"high":-0.85032,"avg":-4.641393,"sd":4.128301,"marketCap":864990000},"quantilePoints":[{"date":"2024-10-04","current":-5.327624,"twenty":-5.327624,"median":-5.327624,"eighty":-5.327624,"marketCap":342006831},{"date":"2024-10-11","current":-5.369409,"twenty":-5.463426,"median":-5.390302,"eighty":-5.369409,"marketCap":344689237},{"date":"2024-10-18","current":-5.076912,"twenty":-5.494765,"median":-5.390302,"eighty":-5.327624,"marketCap":325912392},{"date":"2024-10-25","current":-4.85754,"twenty":-5.463426,"median":-5.327624,"eighty":-5.014234,"marketCap":311829757},{"date":"2024-10-31","current":-4.094958,"twenty":-5.404927,"median":-5.238831,"eighty":-4.776059,"marketCap":262875838},{"date":"2024-11-08","current":-3.677105,"twenty":-5.390302,"median":-5.014234,"eighty":-4.074065,"marketCap":236051773},{"date":"2024-11-15","current":-3.107258,"twenty":-5.373588,"median":-4.888879,"eighty":-3.806639,"marketCap":214779913},{"date":"2024-11-22","current":-2.917613,"twenty":-5.335981,"median":-4.293438,"eighty":-3.619939,"marketCap":201671280},{"date":"2024-11-29","current":-3.141297,"twenty":-5.327624,"median":-4.220314,"eighty":-3.127681,"marketCap":217132744},{"date":"2024-12-06","current":-2.830085,"twenty":-5.277482,"median":-3.974826,"eighty":-3.040153,"marketCap":195621141},{"date":"2024-12-13","current":-2.742557,"twenty":-5.237786,"median":-3.781569,"eighty":-2.995417,"marketCap":189571003},{"date":"2024-12-20","current":-1.896449,"twenty":-5.13959,"median":-3.671882,"eighty":-2.96235,"marketCap":131086332},{"date":"2024-12-27","current":-2.207661,"twenty":-5.051841,"median":-3.301766,"eighty":-2.921503,"marketCap":152597935},{"date":"2025-01-03","current":-2.013153,"twenty":-5.003788,"median":-3.151022,"eighty":-2.57139,"marketCap":139153183},{"date":"2025-01-10","current":-1.818646,"twenty":-4.962003,"median":-3.124277,"eighty":-2.236837,"marketCap":125708431},{"date":"2025-01-17","current":-1.954801,"twenty":-4.920218,"median":-3.063494,"eighty":-2.032604,"marketCap":135119757},{"date":"2025-01-24","current":-1.770019,"twenty":-4.870076,"median":-3.005142,"eighty":-1.952856,"marketCap":122347243},{"date":"2025-01-31","current":-1.876998,"twenty":-4.531614,"median":-2.995417,"eighty":-1.91979,"marketCap":129741856},{"date":"2025-02-07","current":-1.701941,"twenty":-4.324777,"median":-2.96624,"eighty":-1.892559,"marketCap":117641580},{"date":"2025-02-14","current":-1.546335,"twenty":-4.251653,"median":-2.932201,"eighty":-1.865328,"marketCap":106885778},{"date":"2025-02-21","current":-1.400454,"twenty":-4.228671,"median":-2.873849,"eighty":-1.840042,"marketCap":96802214},{"date":"2025-02-28","current":-1.351828,"twenty":-4.1451,"median":-2.528598,"eighty":-1.818646,"marketCap":93441026},{"date":"2025-03-07","current":-1.429631,"twenty":-4.03228,"median":-2.256288,"eighty":-1.756403,"marketCap":98818927},{"date":"2025-03-14","current":-1.293475,"twenty":-3.971692,"median":-2.18821,"eighty":-1.542445,"marketCap":89407600},{"date":"2025-03-21","current":-1.244848,"twenty":-3.871407,"median":-2.022879,"eighty":-1.474368,"marketCap":86046412},{"date":"2025-03-28","current":-1.159638,"twenty":-3.794104,"median":-1.954801,"eighty":-1.429631,"marketCap":85693751},{"date":"2025-04-04","current":-1.050066,"twenty":-3.724618,"median":-1.940213,"eighty":-1.381004,"marketCap":77596704},{"date":"2025-04-11","current":-1.059197,"twenty":-3.680923,"median":-1.925625,"eighty":-1.357663,"marketCap":78271458},{"date":"2025-04-17","current":-1.150507,"twenty":-3.672927,"median":-1.896449,"eighty":-1.324596,"marketCap":85018997},{"date":"2025-04-25","current":-1.187031,"twenty":-3.573219,"median":-1.876998,"eighty":-1.28764,"marketCap":87718013},{"date":"2025-05-02","current":-1.150507,"twenty":-3.328025,"median":-1.867273,"eighty":-1.252628,"marketCap":85018997},{"date":"2025-05-09","current":-1.088206,"twenty":-3.166583,"median":-1.847822,"eighty":-1.218825,"marketCap":80415162},{"date":"2025-05-16","current":-0.872124,"twenty":-3.152968,"median":-1.818646,"eighty":-1.187031,"marketCap":81090920},{"date":"2025-05-23","current":-0.872124,"twenty":-3.141297,"median":-1.818646,"eighty":-1.164325,"marketCap":81090920},{"date":"2025-05-30","current":-0.886659,"twenty":-3.134489,"median":-1.784607,"eighty":-1.159638,"marketCap":82442435},{"date":"2025-06-06","current":-0.901194,"twenty":-3.10434,"median":-1.750568,"eighty":-1.150507,"marketCap":83793951},{"date":"2025-06-13","current":-0.930265,"twenty":-3.086835,"median":-1.590099,"eighty":-1.125277,"marketCap":86496981},{"date":"2025-06-20","current":-0.893927,"twenty":-3.063494,"median":-1.522022,"eighty":-1.106495,"marketCap":83118193},{"date":"2025-06-27","current":-0.91573,"twenty":-3.014867,"median":-1.478258,"eighty":-1.095721,"marketCap":85145466},{"date":"2025-07-03","current":-0.930265,"twenty":-3.007087,"median":-1.439356,"eighty":-1.066502,"marketCap":86496981},{"date":"2025-07-11","current":-0.981139,"twenty":-2.997362,"median":-1.429631,"eighty":-1.007303,"marketCap":91227285},{"date":"2025-07-18","current":-1.061084,"twenty":-2.995417,"median":-1.400454,"eighty":-0.995674,"marketCap":98660619},{"date":"2025-07-25","current":-1.075619,"twenty":-2.995417,"median":-1.376141,"eighty":-1.007303,"marketCap":100012135},{"date":"2025-08-01","current":-1.017477,"twenty":-2.979856,"median":-1.361553,"eighty":-1.016024,"marketCap":94606073},{"date":"2025-08-08","current":-1.220973,"twenty":-2.968185,"median":-1.346965,"eighty":-1.017477,"marketCap":113527288},{"date":"2025-08-15","current":-2.492713,"twenty":-2.95846,"median":-1.351828,"eighty":-1.023291,"marketCap":116554252},{"date":"2025-08-22","current":-3.173861,"twenty":-2.979856,"median":-1.366416,"eighty":-1.024745,"marketCap":148403379},{"date":"2025-08-29","current":-3.333278,"twenty":-3.007087,"median":-1.381004,"eighty":-1.030392,"marketCap":155857430},{"date":"2025-09-05","current":-3.376756,"twenty":-3.075164,"median":-1.400454,"eighty":-1.031929,"marketCap":157890353},{"date":"2025-09-12","current":-3.478204,"twenty":-3.149077,"median":-1.429631,"eighty":-1.042845,"marketCap":162633840},{"date":"2025-09-19","current":-3.246323,"twenty":-3.164638,"median":-1.439356,"eighty":-1.052316,"marketCap":151791584},{"date":"2025-09-26","current":-3.043428,"twenty":-3.197049,"median":-1.483121,"eighty":-1.053816,"marketCap":142304610},{"date":"2025-10-03","current":-2.956473,"twenty":-3.173861,"median":-1.53661,"eighty":-1.057045,"marketCap":138238764},{"date":"2025-10-10","current":-2.739085,"twenty":-3.171828,"median":-1.667902,"eighty":-1.060329,"marketCap":128074149},{"date":"2025-10-17","current":-2.82604,"twenty":-3.164638,"median":-1.760293,"eighty":-1.06543,"marketCap":132139995},{"date":"2025-10-24","current":-2.88401,"twenty":-3.171828,"median":-1.808921,"eighty":-1.072703,"marketCap":134850559},{"date":"2025-10-31","current":-2.88401,"twenty":-3.164638,"median":-1.818646,"eighty":-1.075619,"marketCap":134850559},{"date":"2025-11-07","current":-2.603692,"twenty":-3.149077,"median":-1.838097,"eighty":-1.083171,"marketCap":132139995},{"date":"2025-11-14","current":-2.512362,"twenty":-3.141297,"median":-1.857547,"eighty":-1.088206,"marketCap":127504893},{"date":"2025-11-21","current":-2.324271,"twenty":-3.120874,"median":-1.876998,"eighty":-1.092715,"marketCap":117959072},{"date":"2025-11-28","current":-2.539232,"twenty":-3.101423,"median":-1.886723,"eighty":-1.096373,"marketCap":128868582},{"date":"2025-12-05","current":-2.324271,"twenty":-3.090364,"median":-1.896449,"eighty":-1.097379,"marketCap":117959072},{"date":"2025-12-12","current":-3.090071,"twenty":-3.088805,"median":-1.930487,"eighty":-1.097422,"marketCap":156824200},{"date":"2025-12-19","current":-5.88457,"twenty":-3.141297,"median":-1.945076,"eighty":-1.098568,"marketCap":298647825},{"date":"2025-12-26","current":-4.562679,"twenty":-3.173183,"median":-1.969389,"eighty":-1.101167,"marketCap":231560509},{"date":"2026-01-02","current":-3.763034,"twenty":-3.231831,"median":-2.032604,"eighty":-1.10469,"marketCap":190977740},{"date":"2026-01-09","current":-4.308674,"twenty":-3.260816,"median":-2.195782,"eighty":-1.104852,"marketCap":218669512},{"date":"2026-01-16","current":-3.54666,"twenty":-3.333278,"median":-2.236837,"eighty":-1.106495,"marketCap":179996519},{"date":"2026-01-23","current":-4.619124,"twenty":-3.365162,"median":-2.283966,"eighty":-1.112485,"marketCap":234425175},{"date":"2026-01-30","current":-4.496826,"twenty":-3.449218,"median":-2.324271,"eighty":-1.121288,"marketCap":228218399},{"date":"2026-02-06","current":-4.374527,"twenty":-3.488132,"median":-2.337706,"eighty":-1.123114,"marketCap":222011622},{"date":"2026-02-13","current":-4.957797,"twenty":-3.580579,"median":-2.363428,"eighty":-1.131766,"marketCap":251613172},{"date":"2026-02-20","current":-5.305878,"twenty":-3.670837,"median":-2.397337,"eighty":-1.138397,"marketCap":269278613},{"date":"2026-02-27","current":-6.942798,"twenty":-3.770448,"median":-2.418317,"eighty":-1.146855,"marketCap":352353930},{"date":"2026-03-06","current":-5.895163,"twenty":-3.911674,"median":-2.457761,"eighty":-1.150507,"marketCap":352831374},{"date":"2026-03-13","current":-5.794315,"twenty":-4.006508,"median":-2.512362,"eighty":-1.150507,"marketCap":346795534},{"date":"2026-03-20","current":-5.570843,"twenty":-4.127762,"median":-2.533915,"eighty":-1.150507,"marketCap":333420500},{"date":"2026-03-27","current":-5.674598,"twenty":-4.262099,"median":-2.552667,"eighty":-1.150507,"marketCap":339630337},{"date":"2026-04-02","current":-5.546899,"twenty":-4.40275,"median":-2.552667,"eighty":-1.154159,"marketCap":331987461},{"date":"2026-04-10","current":-6.424826,"twenty":-4.493063,"median":-2.591615,"eighty":-1.159638,"marketCap":384532239},{"date":"2026-04-17","current":-7.039457,"twenty":-4.68874,"median":-2.608653,"eighty":-1.159638,"marketCap":421318549},{"date":"2026-04-24","current":-7.199082,"twenty":-4.833617,"median":-2.724593,"eighty":-1.160328,"marketCap":430872257},{"date":"2026-05-01","current":-7.087345,"twenty":-4.902724,"median":-2.742557,"eighty":-1.16195,"marketCap":424184661},{"date":"2026-05-08","current":-9.505662,"twenty":-5.051841,"median":-2.788531,"eighty":-1.165206,"marketCap":568923347},{"date":"2026-05-15","current":-10.251886,"twenty":-5.174172,"median":-2.811548,"eighty":-1.168769,"marketCap":541217592},{"date":"2026-05-22","current":-9.871852,"twenty":-5.232411,"median":-2.842555,"eighty":-1.168769,"marketCap":521154804},{"date":"2026-05-29","current":-10.260935,"twenty":-5.270935,"median":-2.876764,"eighty":-1.172421,"marketCap":541695277},{"date":"2026-06-05","current":-9.871852,"twenty":-5.327624,"median":-2.88401,"eighty":-1.187031,"marketCap":521154804},{"date":"2026-06-12","current":-9.871852,"twenty":-5.377318,"median":-2.898503,"eighty":-1.187031,"marketCap":521154804},{"date":"2026-06-18","current":-12.299862,"twenty":-5.428177,"median":-2.912995,"eighty":-1.187031,"marketCap":649334330},{"date":"2026-06-26","current":-13.731592,"twenty":-5.484622,"median":-2.927339,"eighty":-1.196162,"marketCap":724918221},{"date":"2026-07-02","current":-14.414918,"twenty":-5.570843,"median":-2.937064,"eighty":-1.198568,"marketCap":760992350},{"date":"2026-07-10","current":-14.989779,"twenty":-5.662848,"median":-2.956494,"eighty":-1.212372,"marketCap":791340427},{"date":"2026-07-17","current":-13.644821,"twenty":-5.682623,"median":-2.970966,"eighty":-1.219913,"marketCap":720337379},{"date":"2026-07-24","current":-13.840057,"twenty":-5.734417,"median":-2.990438,"eighty":-1.223039,"marketCap":730644273},{"date":"2026-07-31","current":-13.102499,"twenty":-5.816662,"median":-2.995417,"eighty":-1.223555,"marketCap":691707117},{"date":"2026-08-07","current":-13.912299,"twenty":-5.930387,"median":-3.014443,"eighty":-1.230727,"marketCap":801682322},{"date":"2026-08-14","current":-14.682008,"twenty":-6.54289,"median":-3.029148,"eighty":-1.235508,"marketCap":846036036},{"date":"2026-08-21","current":-16.964547,"twenty":-6.686846,"median":-3.057921,"eighty":-1.239293,"marketCap":977565060},{"date":"2026-08-28","current":-15.010933,"twenty":-6.894117,"median":-3.079659,"eighty":-1.243636,"marketCap":864990000}],"updateTime":1788188297527},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CLYM\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2663002534","title":"Climb Bio's Upcoming CLYM116 Data Could Support Longer Dosing, Strong Potency, Oppenheimer Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2663002534","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663002534?lang=en_us&edition=fundamental","pubTime":"2026-08-31 23:54","pubTimestamp":1788191674,"startTime":"0","endTime":"0","summary":"Climb Bio's  upcoming CLYM116 data could show strong drug activity, longer-lasting effects and potential dosing every eight to 12 weeks, which would strengthen the drug's position against rivals, Oppenheimer said in a note Monday.The investment firm said it expects Thursday's phase 1 update to show how different doses affect IgA levels and how long the treatment effect lasts.A 60% to 70% drop in IgA at relatively low doses would support its view that CLYM116 may be more potent than competing drugs, Oppenheimer said.CLYM116 may also provide longer-lasting effects by clearing the APRIL protein more effectively, while its ability to use higher doses could further extend the treatment benefit, according to the note.Oppenheimer has an outperform rating and $18 price target for Climb Bio.Price: 14.17, Change: -0.40, Percent Change: -2.75","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","CLYM","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661522069","title":"Climb Bio is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2661522069","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661522069?lang=en_us&edition=fundamental","pubTime":"2026-08-24 18:15","pubTimestamp":1787566500,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CLYM/analyst-ratings","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","CLYM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660746423","title":"Climb Bio Price Target Maintained with a $20.00/Share by Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2660746423","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660746423?lang=en_us&edition=fundamental","pubTime":"2026-08-19 20:56","pubTimestamp":1787144160,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CLYM/analyst-ratings","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","CLYM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660488079","title":"U.S. Research Roundup- Berkshire Hathaway, Exxon Mobil, Honeywell Technologies","url":"https://stock-news.laohu8.com/highlight/detail?id=2660488079","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660488079?lang=en_us&edition=fundamental","pubTime":"2026-08-17 16:16","pubTimestamp":1786954612,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP- Berkshire Hathaway, Exxon Mobil, Honeywell TechnologiesAug 17 (Reuters)-Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nL4N44E0FK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CCAP","ESS","DELL","CRWD","TINY","CHPS","AEP","HON","DNTH","CVX","BYND","EXE","FANG","BMRN","AMAT","CPT","AVB","DAVE","ELVN","AMLX","CBRE","APA","AVBP","XLE","ALAB","ABBV","FHLC","CHRD","TDV","DCH","CLYM","AHR","EAT","BILT","COP","ELS","EOG","PXE","DLTR","DUK","RSPS","DVN","TGT","APP","RDVY","URAN","BCSF","EQT","AMTM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659141812","title":"Climb Bio Partner Mabworks Doses First Patient in China Phase 2 IgA Nephropathy Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2659141812","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659141812?lang=en_us&edition=fundamental","pubTime":"2026-08-14 20:33","pubTimestamp":1786710787,"startTime":"0","endTime":"0","summary":"Climb Bio partner Mabworks doses first patient in China Phase 2 IgA nephropathy trialA Phase 2 trial in China dosed its first patient with immunoglobulin A nephropathy in a study run with Climb Bio.No","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nNDL3SxKqj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CLYM","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659018789","title":"Truist Financial Sticks to Their Buy Rating for Climb Bio (CLYM)","url":"https://stock-news.laohu8.com/highlight/detail?id=2659018789","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659018789?lang=en_us&edition=fundamental","pubTime":"2026-08-13 10:26","pubTimestamp":1786587965,"startTime":"0","endTime":"0","summary":"In a report released on August 11, Danielle Brill from Truist Financial maintained a Buy rating on Climb Bio, with a price target of $25.00. The co...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/truist-financial-sticks-to-their-buy-rating-for-climb-bio-clym-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/truist-financial-sticks-to-their-buy-rating-for-climb-bio-clym-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CLYM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658933738","title":"Guggenheim Reaffirms Their Buy Rating on Climb Bio (CLYM)","url":"https://stock-news.laohu8.com/highlight/detail?id=2658933738","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658933738?lang=en_us&edition=fundamental","pubTime":"2026-08-10 19:36","pubTimestamp":1786361818,"startTime":"0","endTime":"0","summary":"In a report released on August 7, Yatin Suneja from Guggenheim reiterated a Buy rating on Climb Bio, with a price target of $35.00. The company’s s...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/guggenheim-reaffirms-their-buy-rating-on-climb-bio-clym-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/guggenheim-reaffirms-their-buy-rating-on-climb-bio-clym-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CLYM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657662295","title":"RBC Capital Keeps Their Buy Rating on Climb Bio (CLYM)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657662295","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657662295?lang=en_us&edition=fundamental","pubTime":"2026-08-08 09:45","pubTimestamp":1786153542,"startTime":"0","endTime":"0","summary":"In a report released on August 6, Nevin Varghese from RBC Capital maintained a Buy rating on Climb Bio, with a price target of $23.00. The company’...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/rbc-capital-keeps-their-buy-rating-on-climb-bio-clym-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/rbc-capital-keeps-their-buy-rating-on-climb-bio-clym-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CLYM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657464996","title":"Climb Bio Price Target Raised to $25.00/Share from $17.00 by Truist Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2657464996","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657464996?lang=en_us&edition=fundamental","pubTime":"2026-08-07 21:23","pubTimestamp":1786108980,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CLYM/analyst-ratings","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CLYM","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657617666","title":"Analysts Are Bullish on These Healthcare Stocks: Climb Bio (CLYM), Kodiak Sciences (KOD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657617666","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657617666?lang=en_us&edition=fundamental","pubTime":"2026-08-07 05:30","pubTimestamp":1786051816,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Climb Bio (CLYM), Kodiak Sciences (KOD) and Viridian...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-climb-bio-clym-kodiak-sciences-kod-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-climb-bio-clym-kodiak-sciences-kod-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","KOD","BK4139","CLYM","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657300635","title":"Climb Bio Initiates Phase 2 Clym116 Trial in IgA Nephropathy in Q3 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2657300635","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657300635?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:36","pubTimestamp":1786016201,"startTime":"0","endTime":"0","summary":"Climb Bio initiates Phase 2 CLYM116 trial in IgA nephropathy in Q3 2026Climb Bio flagged initial Phase 1 data for anti-APRIL antibody CLYM116 in healthy volunteers for presentation on Sept. 3, 2026.Ea","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL23hq93:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CLYM","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657633078","title":"Climb Bio Q2 EPS $(0.18) Beats $(0.21) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2657633078","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657633078?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:33","pubTimestamp":1786016008,"startTime":"0","endTime":"0","summary":"Climb Bio (NASDAQ:CLYM) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.21) by 14.29 percent. This is a 38.46 percent decrease over losses of $(0.13) per share from the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/60989405/climb-bio-q2-eps-0-18-beats-0-21-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CLYM","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657331716","title":"Climb Bio Q2 Net Loss Widens on Pipeline Advancement","url":"https://stock-news.laohu8.com/highlight/detail?id=2657331716","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657331716?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:29","pubTimestamp":1786015790,"startTime":"0","endTime":"0","summary":"Climb Bio Q2 net loss widens on pipeline advancementOverviewUS biotechnology firm's Q2 net loss widened yr/yr as operating expenses increasedCompany completed $110 mln private placement, extending cas","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4430JV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TYRA","CLYM","IBRN","BK4539","DNTH","ELVN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657638294","title":"Climb Bio Q2 FY26 Net Loss Widens 55.73% to $13.5 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657638294","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657638294?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:11","pubTimestamp":1786014715,"startTime":"0","endTime":"0","summary":"Climb Bio Q2 FY26 net loss widens 55.73% to $13.5 millionClimb Bio posted a GAAP net loss of USD 13.5 million, widening from USD 8.67 million a year earlier.R&D expense rose to USD 9.71 million from U","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL9WXQdp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","CLYM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657802366","title":"Climb Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2657802366","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657802366?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:00","pubTimestamp":1786014006,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nTUA6PSZ0J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4539","CLYM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657633913","title":"Climb Bio - Financing Extends Cash Runway into Second Half of 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2657633913","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657633913?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:00","pubTimestamp":1786014006,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nTUA6PSZ0J:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4539","CLYM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657680472","title":"Climb Bio Inc Q2 Income from Operations USD -15.359 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657680472","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657680472?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:00","pubTimestamp":1786014006,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nPLXP3D4KF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4539","CLYM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656308309","title":"Climb Bio Offers Compelling, Data-Rich H2 With Multiple Near-term Catalysts Across Two Programs, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2656308309","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656308309?lang=en_us&edition=fundamental","pubTime":"2026-08-03 23:40","pubTimestamp":1785771618,"startTime":"0","endTime":"0","summary":"Climb Bio  offers a compelling, data-rich H2, with several near-term catalysts across two differentiated programs in highly unmet need B-cell mediated diseases, RBC Capital Markets said in a Monday research note.RBC said that the proof-of-concept data for the company's Budoprutug anti-CD19 monoclonal antibody in primary membranous nephropathy from low dose has demonstrated early signals of efficacy, with recent immune thrombocytopenia data further de-risking the safety profile, suggesting Budoprutug can be dosed even higher.RBC said it sees out-year sales of about $700 million from Budoprutug across indications of primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus.RBC further said that the company's \"CLYM116 anti-APRIL mechanism is de-risked\" reflecting clinical and commercial validation, with sweeper Fc engineering potentially placing it competitively in the crowded IgA nephropathy market.RBC initiated its coverage on the company's stock with an ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BK4539","CLYM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656276113","title":"Climb Bio Inc : RBC Initiates Coverage with Outperform Rating; Target Price $23","url":"https://stock-news.laohu8.com/highlight/detail?id=2656276113","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656276113?lang=en_us&edition=fundamental","pubTime":"2026-08-03 17:46","pubTimestamp":1785750419,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nFWN4400OJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CLYM","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655780472","title":"Climb Bio’s Budoprutug Trial Completion Sets Stage for Next Investor Catalyst","url":"https://stock-news.laohu8.com/highlight/detail?id=2655780472","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655780472?lang=en_us&edition=fundamental","pubTime":"2026-07-31 00:30","pubTimestamp":1785429047,"startTime":"0","endTime":"0","summary":"Climb Bio, Inc. ($CLYM) announced an update on their ongoing clinical study. Climb Bio, Inc. (CLYM) has completed a Phase 1 study called “A Phase 1...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/climb-bios-budoprutug-trial-completion-sets-stage-for-next-investor-catalyst?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/climb-bios-budoprutug-trial-completion-sets-stage-for-next-investor-catalyst?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","CLYM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":1,"totalSize":105,"code":"91000000","status":"200"}]}}